The 'ChatGPT for doctors,' OpenEvidence, was valued at $15 billion in a new funding round
Executive Take
A three-year-old startup now worth $15 billion shows how fast AI tools can lock in a professional audience doctors trust daily. Big AI labs building their own healthcare products makes OpenEvidence a tempting shortcut acquisition, not just a standalone bet.
Executive Summary
AI health search startup OpenEvidence raised $250 million from hospital systems and Andreessen Horowitz, valuing the company at $15 billion, up from $12 billion in January. More than two-thirds of US doctors reportedly use the tool. Nvidia and Anthropic are among its partners. The founder, Daniel Nadler, may be open to a sale.
Why It Matters
AI and technology leaders should watch this as a sign that vertical AI tools with real daily usage, not just flashy demos, are commanding huge valuations and acquisition interest. Healthcare and enterprise leaders should note how fast trusted AI tools can embed into critical workflows.
Bizquad Perspective
The real signal isn't the $15 billion price tag, it's that OpenEvidence is quietly becoming essential infrastructure doctors can't easily switch away from, which is worth more than any valuation number.